<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305888</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1148</org_study_id>
    <nct_id>NCT02305888</nct_id>
  </id_info>
  <brief_title>Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively</brief_title>
  <official_title>Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1%
      for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and
      trunk/extremities, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions)</measure>
    <time_frame>8 days / From baseline (Day 1) to Day 8</time_frame>
    <description>For face/chest, a DLT was defined as one or more of the following three LSRs:
Crusting Grade 4
Erosion/Ulceration Grade 4
Vesiculation/Pustulation Grade 4
Or two or more of the following five LSRs:
Erythema Grade 4
Crusting Grade 3
Swelling Grade 4
Erosion/Ulceration Grade 3
Vesiculation/Pustulation Grade 3
For scalp a DLT was defined as erosion/ulceration Grade 4
For trunk/extremities a DLT was defined as one or more of the following three LSRs:
Crusting Grade 4
Erosion/Ulceration Grade 4
Vesiculation/Pustulation Grade 4
Or two or more of the following four LSRs:
Crusting Grade 3
Swelling Grade 4
Erosion/Ulceration Grade 3
Vesiculation/Pustulation Grade 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in AK Count Excluding Lesions Identified at Baseline as Hypertrophic/Hyperkeratotic</measure>
    <time_frame>4 weeks and 8 weeks / From baseline to Week 4, and Week 8</time_frame>
    <description>The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at baseline (Day 1), Week 4, and Week 8. This analysis excluded lesions identified at baseline as hypertrophic/hyperkeratotic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in AK Count of Lesions Identified at Baseline as Hypertrophic/Hyperkeratotic</measure>
    <time_frame>4 weeks and 8 weeks / From baseline to Week 4, and Week 8</time_frame>
    <description>Hypertrophic/Hyperkeratotic lesions were identified at baseline (Day 1), Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Clearance of AKs</measure>
    <time_frame>8 weeks</time_frame>
    <description>Complete clearance was defined as no clinically visible AKs. This analysis excluded lesions identified at baseline as hypertrophic/hyperkeratotic.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>LEO 43204, 0.018% once daily for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 43204, 0.037% once daily for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 43204, 0.1% once daily for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204</intervention_name>
    <description>Treatment of actinic keratosis</description>
    <arm_group_label>LEO 43204, 0.018% once daily for 3 days</arm_group_label>
    <arm_group_label>LEO 43204, 0.037% once daily for 3 days</arm_group_label>
    <arm_group_label>LEO 43204, 0.1% once daily for 3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects with 5 to 20 clinically typical, visible and, discrete, nonhyperkeratotic and
        non-hypertrophic AKs within a selected treatment area of sun-damaged skin on either:

          -  The full face

          -  The full balding scalp

          -  A contiguous area of approximately 250 cm2 on trunk or extremities

        Exclusion Criteria:

        Location of the treatment area (full face, full balding scalp or chest) within 5 cm of an
        incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC) or SCC.

        Previously assigned treatment in this clinical trial or previously participated in a
        clinical trial in the LEO 43204 programme.

        Treatment with ingenol mebutate gel in the selected treatment area within the last 12
        months

        Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous
        horns) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous
        occasions).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Siegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Island Skin Cancer and Dermatologic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Island Skin Cancer and Dermatologic Surgery</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <results_first_submitted>February 12, 2019</results_first_submitted>
  <results_first_submitted_qc>February 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <disposition_first_submitted>August 1, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 1, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 2, 2016</disposition_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LEO 43204 0.018% Face/Chest</title>
          <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
        </group>
        <group group_id="P2">
          <title>LEO 43204 0.037% Scalp</title>
          <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
        </group>
        <group group_id="P3">
          <title>LEO 43204 0.1% Trunk/Extremities</title>
          <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population was based on the full analysis set, defined as all participants who assigned to treatment and who met the inclusion criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>LEO 43204 0.018% Face/Chest</title>
          <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
        </group>
        <group group_id="B2">
          <title>LEO 43204 0.037% Scalp</title>
          <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
        </group>
        <group group_id="B3">
          <title>LEO 43204 0.1% Trunk/Extremities</title>
          <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="8.8"/>
                    <measurement group_id="B2" value="67.7" spread="9.6"/>
                    <measurement group_id="B3" value="66.7" spread="9.6"/>
                    <measurement group_id="B4" value="66.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions)</title>
        <description>For face/chest, a DLT was defined as one or more of the following three LSRs:
Crusting Grade 4
Erosion/Ulceration Grade 4
Vesiculation/Pustulation Grade 4
Or two or more of the following five LSRs:
Erythema Grade 4
Crusting Grade 3
Swelling Grade 4
Erosion/Ulceration Grade 3
Vesiculation/Pustulation Grade 3
For scalp a DLT was defined as erosion/ulceration Grade 4
For trunk/extremities a DLT was defined as one or more of the following three LSRs:
Crusting Grade 4
Erosion/Ulceration Grade 4
Vesiculation/Pustulation Grade 4
Or two or more of the following four LSRs:
Crusting Grade 3
Swelling Grade 4
Erosion/Ulceration Grade 3
Vesiculation/Pustulation Grade 3</description>
        <time_frame>8 days / From baseline (Day 1) to Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.018% Face/Chest</title>
            <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
          </group>
          <group group_id="O2">
            <title>LEO 43204 0.037% Scalp</title>
            <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
          </group>
          <group group_id="O3">
            <title>LEO 43204 0.1% Trunk/Extremities</title>
            <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions)</title>
          <description>For face/chest, a DLT was defined as one or more of the following three LSRs:
Crusting Grade 4
Erosion/Ulceration Grade 4
Vesiculation/Pustulation Grade 4
Or two or more of the following five LSRs:
Erythema Grade 4
Crusting Grade 3
Swelling Grade 4
Erosion/Ulceration Grade 3
Vesiculation/Pustulation Grade 3
For scalp a DLT was defined as erosion/ulceration Grade 4
For trunk/extremities a DLT was defined as one or more of the following three LSRs:
Crusting Grade 4
Erosion/Ulceration Grade 4
Vesiculation/Pustulation Grade 4
Or two or more of the following four LSRs:
Crusting Grade 3
Swelling Grade 4
Erosion/Ulceration Grade 3
Vesiculation/Pustulation Grade 3</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in AK Count Excluding Lesions Identified at Baseline as Hypertrophic/Hyperkeratotic</title>
        <description>The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at baseline (Day 1), Week 4, and Week 8. This analysis excluded lesions identified at baseline as hypertrophic/hyperkeratotic.</description>
        <time_frame>4 weeks and 8 weeks / From baseline to Week 4, and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.018% Face/Chest</title>
            <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
          </group>
          <group group_id="O2">
            <title>LEO 43204 0.037% Scalp</title>
            <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
          </group>
          <group group_id="O3">
            <title>LEO 43204 0.1% Trunk/Extremities</title>
            <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in AK Count Excluding Lesions Identified at Baseline as Hypertrophic/Hyperkeratotic</title>
          <description>The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at baseline (Day 1), Week 4, and Week 8. This analysis excluded lesions identified at baseline as hypertrophic/hyperkeratotic.</description>
          <units>percentage of reduction</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="74.7" upper_limit="86.1"/>
                    <measurement group_id="O2" value="78.8" lower_limit="71.6" upper_limit="84.1"/>
                    <measurement group_id="O3" value="59.0" lower_limit="50.0" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="70.9" upper_limit="84.7"/>
                    <measurement group_id="O2" value="76.3" lower_limit="66.7" upper_limit="83.1"/>
                    <measurement group_id="O3" value="69.1" lower_limit="60.3" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in AK Count of Lesions Identified at Baseline as Hypertrophic/Hyperkeratotic</title>
        <description>Hypertrophic/Hyperkeratotic lesions were identified at baseline (Day 1), Week 4 and Week 8.</description>
        <time_frame>4 weeks and 8 weeks / From baseline to Week 4, and Week 8</time_frame>
        <population>For this efficacy analysis only participants with lesions identified as hypertrophic/hyperkeratotic at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.018% Face/Chest</title>
            <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
          </group>
          <group group_id="O2">
            <title>LEO 43204 0.037% Scalp</title>
            <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
          </group>
          <group group_id="O3">
            <title>LEO 43204 0.1% Trunk/Extremities</title>
            <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in AK Count of Lesions Identified at Baseline as Hypertrophic/Hyperkeratotic</title>
          <description>Hypertrophic/Hyperkeratotic lesions were identified at baseline (Day 1), Week 4 and Week 8.</description>
          <population>For this efficacy analysis only participants with lesions identified as hypertrophic/hyperkeratotic at baseline were included in the analysis.</population>
          <units>percentage of reduction</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" lower_limit="38.7" upper_limit="92.6"/>
                    <measurement group_id="O2" value="58.1" lower_limit="6.8" upper_limit="81.2"/>
                    <measurement group_id="O3" value="36.0" lower_limit="1.3" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="4.5" upper_limit="89.6"/>
                    <measurement group_id="O2" value="62.5" lower_limit="-13.2" upper_limit="87.5"/>
                    <measurement group_id="O3" value="39.2" lower_limit="7.9" upper_limit="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Clearance of AKs</title>
        <description>Complete clearance was defined as no clinically visible AKs. This analysis excluded lesions identified at baseline as hypertrophic/hyperkeratotic.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 43204 0.018% Face/Chest</title>
            <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
          </group>
          <group group_id="O2">
            <title>LEO 43204 0.037% Scalp</title>
            <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
          </group>
          <group group_id="O3">
            <title>LEO 43204 0.1% Trunk/Extremities</title>
            <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Clearance of AKs</title>
          <description>Complete clearance was defined as no clinically visible AKs. This analysis excluded lesions identified at baseline as hypertrophic/hyperkeratotic.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" lower_limit="24.7" upper_limit="49.6"/>
                    <measurement group_id="O2" value="39.7" lower_limit="27.6" upper_limit="52.8"/>
                    <measurement group_id="O3" value="22.6" lower_limit="12.9" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to Week 8Â±7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LEO 43204 0.018% Face/Chest</title>
          <description>Treatment with LEO 43204 0.018% gel once daily for 3 consecutive days on the full face or a contiguous area on the chest of approximately 250 cm2.</description>
        </group>
        <group group_id="E2">
          <title>LEO 43204 0.037% Scalp</title>
          <description>Treatment with LEO 43204 0.037% gel once daily for 3 consecutive days on the full balding scalp of an area greater than 25 cm2 and up to approximately 250 cm2.</description>
        </group>
        <group group_id="E3">
          <title>LEO 43204 0.1% Trunk/Extremities</title>
          <description>Treatment with LEO 43204 0.1% gel once daily for 3 consecutive days on a contiguous area of approximately 250 cm2 on trunk or extremities (excluding chest).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Application site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Specialist</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

